Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2014 | 22 | 1 | 37-50

Article title

Selected classical and novel antiepileptic drugs – mechanisms of action, neuroprotection, and effectiveness in epileptic and non-epileptic conditions


Title variants

Languages of publication



Introduction. One of the most common neurological disorders is epilepsy, characterised by recurrent spontaneus seizures. Although not fully efficient in ca 30% of patients, pharmacologic treatment of epilepsy plays an important therapeutic approach not only against epilepsy.Aim. To provide data on the mechanism of action, activity and neuroprotective efficacy in experimental conditions, clinical efficacy against epilepsy and non-epileptic diseases of major, classical and newer antiepileptic drugs (AEDs – lamotrigine, topiramate, levetiracetam, valproate and carbamazepine).Methods. A literature search for publications written in English, preferably published within a period of the last fifteen years, using the key words listed below.Review. The majority of AEDs possess more than one mechanism of action. They exert their effect by acting on various receptors (different types of glutamatergic and mainly GABAA receptors), neurotransmitters (mainly glutamate or GABA) and voltage-gated ion channels (sodium or calcium ion channels). All reviewed AEDs possess neuroprotective activity, the weakest being carbamazepine. Apart from epilepsy, AEDs may be also used in the pharmacotherapy of migraine, neuropathic pain, spasticity, psychiatric disorders and Parkinsons's or Alzheimer's diseases.Conclusions. As highlighted above, around 30% of epileptic patients do not substantially benefit from AEDs. It is possible that rational combinations of AEDs, based upon experimental studies, could improve this outcome. The neuroprotective effects of AEDs may point to their disease-modifying activity.









Physical description


1 - 6 - 2014
1 - 3 - 2015
10 - 1 - 2014
20 - 3 - 2014


  • Department of Pathophysiology, Medical University of Lublin, Lublin
  • Clinic of Paediatrics, Endocrinology and Neurology, Medical University of Lublin, Lublin
  • Department of Pathophysiology, Medical University of Lublin, Lublin
  • Department of Pathophysiology, Medical University of Lublin, Lublin
  • Department of Pathophysiology, Medical University of Lublin, Lublin
  • Department of Physiopathology, Institute of Rural Health, Lublin, Poland


  • Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., Tomson T.:Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res., 2004, 61: 1–48.[Crossref][PubMed]
  • Biton V., Bourgeois B.F.:Topiramate in patients with juvenile myoclonic epilepsy. Arch. Neurol., 2005, 11: 1705–1708.[Crossref]
  • Blaheta R.A., Michaelis M., Hernaiz Driever P., Cinatl J. Jr.:Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies. Med. Res. Rev., 2005, 25: 383–397.[PubMed][Crossref]
  • Bolanos A.R., Sarkisian M., Yang Y., Hori A., Heimers S.L., Mikati M. et al.:Comparison of valproate and Phenobarbital treatment after status epilepticus in rats. Neurology, 1998, 51: 41–48.[PubMed][Crossref]
  • Bootsma H.P.R., Coolen F., Aldenkamp A.P., Arends J., Diepman L., Hulsman J. et al.:Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to tertiary epilepsy center. Epilepsy Behav., 2004, 5: 380–387.[PubMed][Crossref]
  • Borowicz K.K., Banach M., Zarczuk R., Lukasik D., Łuszczki J.J., Czuczwar S.J.:Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model. Psychopharmacology, 2007a, 195: 167–174.[Crossref][PubMed]
  • Borowicz K.K., Furmanek-Karwowska K., Sawicka K., Łuszczki J.J., Czuczwar S.J.:Chronically administered fluoxetine enhances the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model. Eur. J. Pharmacol., 2007b, 567: 77–82.
  • Borowicz K.K., Łuszczki J., Czuczwar S.J.:2-Chloroadenosine, a preferential agonist of adenosine A1 receptors, enhances the anticonvulsant activity of carbamazepine and clonazepam in mice. Eur. Neuropsychopharmacol., 2002a, 12: 173–179.
  • Borowicz K.K., Świąder M., Zgrajka W., Sawulski C., Turski W.A., Czuczwar S.J.:Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. J. Physiol. Pharmacol., 2002b, 53: 859–869.
  • Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F. et al.:A randomized, placebo-controlled 12-month trial of divalproex and lithium in the treatment of outpatients with bipolar I disorder. Arch. Gen. Psychiatry, 2000, 57: 481–489.[PubMed][Crossref]
  • Brandt C., Gastens A.M., Sun M.Z., Hausknecht M., Löscher W.:Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology, 2006, 51: 789–804.[Crossref][PubMed]
  • Brodie M.J., Schachter S.C.:Fast Facts. Epilepsy. 2nd edn. Health Press, Oxford 2001.
  • Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monagham E., Rudd G.D.:A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J. Clin. Psychiatry, 1999, 60: 79–88.[Crossref]
  • Calabresi P., Stefani A., Marfia G.A., Hainsworth A.H., Centonze D., Saulle E. et al.:Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects. Exp. Neurol., 2000, 162: 171–179.[Crossref][PubMed]
  • Cascino G.D.:When drugs and surgery don't work. Epilepsia, 2008, 49 (Suppl 9): 79–84.[Crossref]
  • Chrościńska M., Jargiełło M., Czuczwar S.J.:Influence of caffeine on the protective action of some conventional and novel antiepileptic drugs – an experimental evidence. Pharmacol. Rep., 2007, 59: 118.
  • Cinatl J. Jr., Kotchetkov R., Blaheta R.A., Driever P.H., Vogel J.-U., Cinatl J.:Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferonalpha. Int. J. Oncol., 2002, 20: 97–106.
  • Conti C.F., de Oliveira M.M., Valbuza J.S., Prado L.B., de Carvalho L.B., do Prado G.F.:Anticonvulsants to treat idiopathic restless legs syndrome. Arq. Neuropsiquiatr., 2008, 66: 431–435.[PubMed][Crossref]
  • Crumrine R.C., Bergstrand K., Cooper A.T., Faison W.L., Cooper B.R.:Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke, 1997, 28: 2230–2236. discussion 2237.
  • Curia G., Longo D., Biagini G., Jones R.S.G., Avoli M.:The pilocarpine model of temporal lobe epilepsy. J. Neurosci. Methods, 2008, 172: 143–157.[Crossref]
  • Czapinski P., Blaszczyk B., Czuczwar S.J.:Mechanisms of action of antiepileptic drugs. Curr. Top. Med. Chem., 2005, 5: 3–14.[PubMed][Crossref]
  • Czuczwar P., Kaczmarczyk P., Czuczwar S.J.:New experimental data on the combinations of antiepileptic drugs. Epileptologia, 2009a, 17: 247–254.
  • Czuczwar S.J., Kaplanski J., Swiderska-Dziewit G., Gergont A., Kroczka S., Kacinski M.:Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. Expert Opin. Drug Metab. Toxicol., 2009b, 5: 131–136.[Crossref]
  • Dahlof C., Loder E., Diamond M., Rupnow M., Papadopoulos G., Mao L.:The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual. Life Outcomes, 2007, 4: 56.
  • De Sarro G., Gratteri S., Bonacci F., Musumeci S.A., Elia M., De Sarro A.:Topiramate potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. Eur. J. Pharmacol., 2000, 388: 163–170.[Crossref][PubMed]
  • Deckers C.L.P., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H. et al.:Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. Epilepsia, 2000, 41: 1364–1374.[PubMed][Crossref]
  • Dinnerstein E., Jobst B.C., Williamson P.D.:Lamotrigine intoxication provoking status epilepticus in an adult with localization-related epilepsy. Arch. Neurol., 2007, 64: 1344–1346.[Crossref]
  • Doheny H.C., Whittington M.A., Jefferys J.G., Patsalos P.N.:A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy. Br. J. Pharmacol., 2002, 135: 1425–1434.[PubMed]
  • Domingues R.B., Kuster G.W., Aquino C.C.:Treatment of trigeminal neuralgia with low doses of topiramate. Arq. Neuropsiquiatr., 2007, 65: 792–794.[PubMed][Crossref]
  • Dudra-Jastrzębska M., Andres-Mach M.M., Łuszczki J.J., Czuczwar S.J.:Mood disorders in patients with epilepsy. Pharmacol. Rep., 2007, 59: 369–378.
  • Eisensehr I., Ehrenberg B.L., Rogge Solti S., Noachtar S.:Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow release levodopa/benserazid. J. Neurol., 2004, 5: 579–583.[Crossref]
  • Eyal S., Lamb J.G., Smith-Yockman M., Yagen B., Fibach E., Altschuler Y. et al.:The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Brit. J. Pharmacol., 2006, 149: 250–260.[Crossref]
  • Ferraro D., Di Trapani G.:Topiramate in the prevention of pediatric migraine: literature review. J. Headache Pain, 2008, 9: 147–150.[Crossref]
  • Fisher R.S., van Emde Boas W., Blume W., Elger C., Genton P., Lee P. et al.:Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia, 2005, 46: 470–472.[Crossref]
  • Follett P.L., Deng W., Dai W., Talos D.M., Massillon L.J., Rosenberg P.A. et al.:Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: A protective role for topiramate. J. Neurosci., 2004, 24: 4412–4420.[Crossref]
  • French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L. et al.:Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 2004, 62: 1261–1273.[PubMed]
  • Frye M.A., Ketter T.A., Kimbrell T.A., Dunn R.T., Speer A.M., Osuch E.A. et al.:A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol., 2000, 20: 607–614.[Crossref]
  • Gilron I., Booher S.L., Rowan J.S., Max M.B.:Topiramate in trigeminal neuralgia: a randomized, placebo-controlled, multiple crossover pilot study. Clin. Neuropharmacol., 2001, 24: 109–112.[PubMed][Crossref]
  • Gracia-Naya M., Latorre-Jiménez A.M., Ríos-Gómez C., Santos-Lasaosa S., Mauri J.A., Sánchez-Valiente S. et al.:Topiramate in chronic daily headache due to migraine. Rev. Neurol., 2007, 45: 456–459.
  • Hanaya R., Sasa M., Ujihara H., Ishihara K., Serikawa T., Iida K. et al.:Suppression by topiramate of epileptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro. Brain Res., 1998, 789: 274–282.
  • Hanon E., Klitgaard H.:Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure, 2001, 10: 287–293.[PubMed][Crossref]
  • Hawker K., Frohman E., Racke M.:Levetiracetam for phasic spasticity in multiple sclerosis. Arch. Neurol., 2003, 60: 1772–1774.[PubMed][Crossref]
  • Jankiewicz K., Chrościńska-Krawczyk M., Błaszczyk B., Czuczwar S.J:Kofeina a leki przeciwpadaczkowe: dane doświadczalne i kliniczne. Przeg. Lek., 2007, 64: 965–967.
  • Jędrzejczak J., Kuncikova M., Magureanu S., VIPe Study Group:An observational study of first-line valproate monotherapy in focal epilepsy. Eur. J. Neurol., 2008, 15: 66–72.
  • Kelly K., Stephen L.J., Sills G.J., Brodie M.J.:Topiramate in patients with learning disability and refractory epilepsy. Epilepsia, 2002, 43: 399–402.[Crossref][PubMed]
  • Koinig H., Morimoto Y., Zornow M.H.:The combination of lamotrigine and mild hypothermia prevents ischemia-induced increase in hippocampal glutamate. J. Neurosurg. Anesthesiol., 2001, 13: 106–112.[Crossref]
  • Kwan P., Brodie M.:Early identification of refractory epilepsy. N. Engl. J. Med., 2000, 342: 314–319.[Crossref]
  • Lampl C., Katsarava Z., Diener H.C., Limmroth V.:Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J. Neurol. Neurosurg. Psychiat., 2005, 76: 1730–1732.[Crossref]
  • Lasoń W., Dudra-Jastrzębska M., Rejdak K., Czuczwar S.J.:Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions – an update. Pharmacol. Rep., 2011, 63: 271–292.[Crossref][PubMed]
  • Leach J.P., Brodie M.J.:New antiepileptic drugs – an explosion of activity. Seizure, 1995, 4: 5–17.[PubMed][Crossref]
  • Lee C.Y., Fu W.M., Chen C.C., Su M.J., Liou H.H.:Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia, 2008a, 49: 588–597.[Crossref]
  • Lee J.H., Hwang Y.S., Shin J.J., Kim T.H., Shin H.S., Park S.K.:Surgical complications of epilepsy surgery procedures: experience of 179 procedures in a single institute. J. Korean Neurosurg. Soc., 2008b, 44: 234–239.
  • Lee H.O., Koh E.J., Oh Y.M., Park S.S., Kwon K.H., Choi H.Y.:Effect of vagus nerve stimulation in post-traumatic epilepsy and failed epilepsy surgery: preliminary report. J. Korean Neurosurg. Soc., 2008c, 44: 196–198.
  • Lee W.T., Shen Y.Z., Chang C.:Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy. Neuroscience, 2000, 95: 89–95.[PubMed]
  • Leker R.R., Neufeld M.Y.:Anti-epileptic drugs as possible neuroprotectants in cerebral ischemia. Brain Res., 2003, 42: 187–203.[Crossref]
  • Li X., Ketter T.A., Frye M.A.:Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J. Affect. Disord., 2002, 69: 1–14.[Crossref]
  • Lin D., Mok H., Yatham L.N.:Polytherapy in bipolar disorder. CNS Drugs, 2006, 20: 29–42.[Crossref][PubMed]
  • Liu Y., Barks J.D., Xu G., Silverstein F.S.:Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke, 2004, 35: 1460–1465.[PubMed][Crossref]
  • Löscher W.:Basic pharmacology of valproate. CNS Drugs, 2002, 16: 669–694.[Crossref][PubMed]
  • Löscher W., Fassbender C.P., Nolting B.:The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res., 1991, 8: 79–94.[Crossref]
  • Löscher W., Potschka H.:Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther., 2002, 301: 7–14.[Crossref]
  • Lukyanetz E.A., Shkryl V.M., Kostyuk P.G.:Selective blockade of N-type calcium channels by levetiracetam. Epilepsia, 2002, 43: 9–18.[Crossref][PubMed]
  • Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A. et al.:The synaptic vesicle protein SV2A in the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA, 2004, 101: 9861–9866.[Crossref]
  • Łuszczki J.J., Czernecki R., Wojtal K., Borowicz K.K., Czuczwar S.J.:Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model. J. Neural Transm., 2008, 115: 1485–1494.[Crossref]
  • Łuszczki J.J., Danysz W., Czuczwar S.J.:Interactions of MRZ 2/576 with febamate, lamotrygine, oxcarbazepine and topiramate in the mouse maximal electroshock – induced seizure model. Pharmacology, 2008, 81: 259–265.[Crossref]
  • Łuszczki J.J., Kozicka M., Świąder M.J., Czuczwar S.J.:2-Chloro-N6-cyclopentyladenosine enhances the anticonvulsant action of carbamazepine in the mouse maximal electroshock-induced seizure model. Pharmacol. Rep., 2005, 57: 787–792.
  • Łuszczki J.J., Sawicka K.M, Kozińska J., Dudra-Jastrzębska M., Czuczwar S.J.:Amiloride enhances the anticonvulsant action of various antiepileptic drugs in the mouse maximal electroshock seizure model. J. Neural. Transm., 2009, 116: 57–66.[Crossref]
  • Łuszczki J.J., Sawicka K.M., Kozinska J., Borowicz K.K., Czuczwar S.J.:Furosemide potentiates the anticonvulsant action of valproate in the mouse maximal electroshock seizure model. Epilepsy Res., 2007a, 76: 66–72.[Crossref][PubMed]
  • Łuszczki J.J., Trojnar M.K., Trojnar M.P., Kimber-Trojnar Ż., Szostakiewicz B., Zadrożniak B. et al.:Effects of three calcium channel antagonists (amlodipine, diltiazem and verapamil) on the protective action of lamotrigine in the mouse maximal electroshock – induced seizure model. Pharmacol. Rep., 2007b, 59: 672–682.[PubMed]
  • Macdonald R.L., Kelly K.M.:Antiepileptic drug mechanisms of action. Epilepsia, 1995, 36: 2–12.[Crossref]
  • Maj R., Fariello R.G., Ukmar G., Varasi M., Pevarello P., McArthur R.A. et al:PNU-151774E protects against kainateinduced status epilepticus and hippocampal lesions in the rat. Eur. J. Pharmacol., 1998, 359: 27–32.[Crossref]
  • Majkowski J.:One-year observation of topiramate in add-on therapy in patients with drug resistant epilepsy. Epileptologia, 2004a, 12: 55–64.
  • Majkowski J.:Advances in characteristics and pathogenesis understanding of drug resistant epilepsy. Epileptologia, 2004b, 12: 137–147.
  • Majkowski J.:The place of epileptology in the contemporary medicine – from research to practice. Epileptologia, 2006, 14: 263–273.
  • Majkowski J., Neto W., Wapenaar R., Van Oene J.:Time course of adverse events in patients with localization – related epilepsy receiving topiramate added to carbamazepine. Epilepsia, 2005, 46: 648–653.[Crossref][PubMed]
  • Małek R., Borowicz K.K., Kimber-Trojnar Z., Sobieszek G., Piskorska B., Czuczwar S.J.:Remacemide – a novel potential antiepileptic drug. Pol. J. Pharmacol., 2003, 55: 691–698.[PubMed]
  • Mapstone T.B.:Vagus nerve stimulation: current concepts. Neurosurg. Focus, 2008, 25: E9.[PubMed][Crossref]
  • Margolin A., Avants S.K., DePhilips D., Kosten T.R.:A preliminary investigation of lamotrygine for cocaine abuse in HIV-sero-positive patients. Am. J. Drug. Alcohol Abuse, 1998, 24: 85–101.[Crossref]
  • Marson A.G., Al-Kharusi A.M., Alwaidh M., Appleton R., Baker G.A., Chadwick D.W. et al:The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randqeomised controlled trial. Lancet, 2007, 369: 1000–1015.[Crossref]
  • Marson A.G., Hutton J.L., Leach J.P., Castillo S., Schmidt D., White S. et al.:Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res., 2001, 46: 259–270.[Crossref][PubMed]
  • Mazarati A.M., Baldwin R., Klitgaard H., Matagne A., Wasterlain C.G.:Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res., 2004, 58: 167–174.[Crossref][PubMed]
  • Morland C., Boldingh K.A., Iversen E.G., Hassel B.:Valproate is neuroprotective against malonate toxicity in rat striatum: An association with augmentation of high-affinity glutamate uptake. J. Cereb. Blood Flow Metab., 2004, 24: 1226–1234.[PubMed]
  • Murakami A., Ishikawa T., Takechi K., Ago J., Matsumoto N., Kamei C.:Effects of certain antiepileptics on behavioral and electromyographic seizure patterns induced by maximal electroshock in mice. J. Pharmacol. Sci., 2007, 104: 56–60.[Crossref]
  • Nakamura J., Tamura S., Kanda T., Ishii A., Ishihara K., Serikawa T. et al.:Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur. J. Pharmacol., 1994, 254: 83–89.[Crossref][PubMed]
  • Niespodziany I., Klitgaard H., Margineanu D.G.:Levetiracetam inhibits the high-voltage-activated Ca2+, current in pyramidal neurones of rat hippocampl slices. Neurosci. Lett., 2001, 306: 5–8.[Crossref][PubMed]
  • Otoul C., Arrigo C., Rijckevorsel K.V., French J.A.:Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin. Neuropharmacol., 2005, 28: 72–78.[Crossref][PubMed]
  • Owens M.J., Nemeroff C.B.:Pharmacology of valproate. Psychopharmacol. Bull., 2003, 37 (Suppl 2): 17–25.[PubMed]
  • Papazisis G., Kallaras K., Kaiki-Astara A., Pourzitaki C., Tzachanis D., Dagklis T. et al.:Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy. Int. J. Neuropsychopharmacol., 2008, 1: 321–329.
  • Patsalos P.N:Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet., 2004, 43: 707–724.[PubMed][Crossref]
  • Perucca E.:Clinically relevant drug interactions with antiepileptic drugs. Brit. J. Clin. Pharmacol., 2006, 61: 246–255.[Crossref]
  • Pitkanen A.:Efficacy of current antiepileptics to prevent neurodegeneration in epilepsy models. Epilepsy Res., 2002, 50: 141–160.[PubMed][Crossref]
  • Remy S., Beck H.:Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain, 2006, 129: 18–35.[Crossref][PubMed]
  • Ren M., Leng Y., Jeong M., Leeds P.R., Chuang D.M.:Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock peotein induction. J. Neurochem., 2004, 89: 1358–1367.[Crossref]
  • Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B. et al.:The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA – and glycine. Br. J. Pharmacol., 2002, 136: 659–672.[PubMed]
  • Sabers A., Gram L.:Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs, 2000, 60: 23–33.[PubMed][Crossref]
  • Sardo P., Ferraro G.:Modulatory effects of nitric oxide-active drugs on the anticonvulsant activity of lamotrigine in an experimental model of partial complex epilepsy in the rat. BMC Neurosci., 2007, 8: 47.[Crossref]
  • Schneiderman J.H.:Topiramate: pharmacokinetics and pharmacodynamics. Can. J. Neurol. Sci., 1998, 25: 3–5.
  • Shuaib A., Mahmood R.H., Wishart T., Kanthan R., Murabit M.A., Iljaz S. et al.:Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Brain Res., 1995, 702: 199–206.
  • Sills G.J., Butler E., Thompson G.G., Brodie M.J.:Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure, 2004, 13: 287–295.[PubMed][Crossref]
  • Sindrup S.H., Jensen T.S.:Pharmacotherapy of trigeminal neuralgia. Clin. J. Pain, 2002, 18: 22–27.[PubMed][Crossref]
  • Skradski S., White H.S.:Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia, 2000, 41: 45–47.[Crossref]
  • Sobaniec W., Kułak W., Strzelecka J., Śmigielska-Kuzia J., Boćkowski L.:A comparative study of vigabatrin vs. carbamazepine in monotherapy of newly diagnosed partial seizures in children. Pharmacol. Rep., 2005, 57: 646–653.[PubMed]
  • Sousa Pda S., Araujo Filho G.M., Garzon E., Sakamoto A.C., Yacubian E.M.:Topiramate for the treatment of juvenile myoclonic epilepsy. Arq. Neuropsiquiatr., 2005, 63: 733–737.[Crossref][PubMed]
  • Stępień K., Tomaszewski M., Czuczwar S.J.:Profile of anti-convulsant activity and neuroprotective effects of novel and potential antiepileptic drugs – an update. Pharmacol. Rep., 2005, 57: 719–733.
  • Suda S., Katsura K., Kanamaru T., Saito M., Katayama Y.:Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation. Eur. J. Pharmacol., 2013, 707: 26–31.
  • Świąder M.J., Łuszczki J.J., Zwolan A., Wielosz M., Czuczwar S.J:Effects of some convulsant agents on the protective activity of TPM against maximal electroshock-induced seizures in mice. Pharmacol. Rep., 2005, 57: 373–379.
  • Tomczyk T., Haberek G., Zuchora B., Jarosławska-Zych A., Kowalczyk M.S., Wielosz M. et al.:Enhanced glutamatergic transmission reduces the anticonvulsant potential of lamotrigine but not of felbamate against tonic-clonic seizures. Pharmacol. Rep., 2007, 59: 462–466.[PubMed]
  • Toth M.:The epsilon theory: a novel synthesis of the underlying molecular and electrophysiological mechanisms of primary generalized epilepsy and the possible mechanism of action of valproate. Med. Hypotheses, 2005, 64: 267–272.[Crossref][PubMed]
  • Trojnar M.K., Małek R., Chrościńska M., Nowak S., Błaszczyk B., Czuczwar S.J.:Neuroprotective effects of antiepileptic drugs. Pol. J. Pharmacol., 2002, 54: 557–566.[PubMed]
  • Tutor-Crespo M.J., Hermida J., Tutor J.C.:Relative proportions of serum carbamazepine and its pharmacologically active 10, 11-epoxy derivative: effect of polytherapy and renal insufficiency. Upsala J. Med. Sci., 2008, 113: 171–180.
  • Vazquez B.:Monotherapy in Epilepsy. Role of the newer antiepileptic drugs. Arch. Neurol., 2004, 61: 1361–1365.[PubMed][Crossref]
  • Vitezic D., Pelcic J.M., Zupan G., Vitezic M., Ljubicic D., Simonic A.:NA+, K+-ATPase activity in the brain of the rats with kainic acid-induced seizures: influence of lamotrigine. Psychiatr. Danub., 2008, 20: 269–276.
  • Wheless J.W., Clarke D.F., Arzimanoglou A., Carpenter D.:Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord., 2007, 9: 353–412.[PubMed]
  • White H.S., Brown SD., Woodhead J.H., Skeen G.A., Wolf H.H.:Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res., 1997, 28: 167–179.[Crossref][PubMed]
  • Wiard R.P., Dickerson M.C., Beek O., Norton R., Cooper B.R.:Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Stroke, 1995, 26: 466–472.[Crossref]
  • Wilby J., Kainth A., Hawkins N., Epstein D., McIntosh H., McDaid C. et al.:Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol. Assessm., 2005, 9: 1–157.[Crossref]
  • Wojtal K., Borowicz K.K., Błaszczyk B., Czuczwar S.J.:Interactions of excitatory amino acid receptor antagonists with antiepileptic drugs in three basic models of experimental epilepsy. Pharmacol. Rep., 2006, 58: 587–598.[PubMed]
  • Xia Q., Sung J., Chowdhury W., Chen C., Hoti N., Shabbeer S.:Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res., 2006, 66: 7237–7244.[Crossref][PubMed]
  • Yang Y., Shuaib A., Li Q., Siddiqui M.M.:Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res., 1998, 804: 169–176.[Crossref]
  • Zaccara G., Messori A., Cincotta M., Burchini G.:Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol. Scand., 2006, 114: 157–168.[PubMed][Crossref]
  • Zakrzewska J.M., Chaudry Z., Nurmikko T.J., Patton D.W., Mullens E.L.:Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double-blind, placebo controlled trial. Pain, 1997, 73: 223–230.[PubMed][Crossref]
  • Zaremba P.D., Białek M., Błaszczyk B., Cioczek P., Czuczwar S.J.:Non-epilepsy uses of antiepileptic drugs. Pharmacol. Rep., 2006, 58: 1–12.[PubMed]
  • Zhang X., Velumian A..A, Jones O.T., Carlen P.L.:Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia, 2000, 41: 52–60.[Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.